Reminder: Invitation to Roche ’s Virtual Neurology Investor Event
We are pleased to invite investors and analysts to participate in our virtual event onMonday, 11 March 2024, highlighting key data presented at 2024 Muscular Dystrophy Association (MDA) and Alzheimer ' s& Parkinson ' s Diseases (AD/PD) conferences. 15:00 – 16:30 CET / 14:00 – 15:30 GMT10:00 – 11:30 AM EDT / 07:00 – 08:30 AM PDT The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for download at 14:00 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor RelationsNeurology franchise updatePaulo Fontoura, Senior Vice President and Global Head of Neuroscience, Immunology, Ophthalmology, Cardiometabolic, Infectious and Rare Diseases Clinical DevelopmentReview of key EMBARK data presented at MDAAlex Murphy, Senior Clinical DirectorReview of key trotinemab and prasinezumab data presented at AD/PDAzad Bonni, MD, PhD, Senior Vice President and Global Head of Neuroscience& Rare Diseases, Roche Pharma Research& Early DevelopmentQ&A Access to virtual event (pre-registration required)Please pre-register for our webinarhere.* Should you be unable to register for the webinar due to your company IT policy, please send an email toinvestor.relations@roche.com. A replay of the webinar will be available via>ir.roche.com*privacy notice Best regards, Bruno EschliHead of Investor Relations Loren KalmHead of Investor Relations, North Amer...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Allergy & Immunology | Alzheimer's | Brain | Cardiology | Conferences | Genetics | Heart | Muscular Dystrophy | Neurology | Opthalmology | Parkinson's Disease | Pharmaceuticals | Rare Diseases | Reflex Sympathetic Dystrophy